Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The only definitive way to diagnose and stage lung cancers is through biopsies
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
